GC（A005250）株式概要グリーンクロス・ホールディングスはバイオテクノロジー企業である。 詳細A005250 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金1/6リスク分析過去5年間で収益は年間18.3%減少しました。 利払いは収益で十分にカバーされない 不安定な配当実績 すべてのリスクチェックを見るA005250 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW460,775 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA460,775 investors already sharing narrativesYour Fair Value₩Current Price₩10.32k95.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-89b3t2016201920222025202620282031Revenue ₩3.3tEarnings ₩594.0bAdvancedSet Fair ValueView all narrativesGC Corp. 競合他社Medy-ToxSymbol: KOSDAQ:A086900Market cap: ₩445.8bBioNoteSymbol: KOSE:A377740Market cap: ₩492.3bOnconic TherapeuticsSymbol: KOSDAQ:A476060Market cap: ₩635.7bHEM PharmaSymbol: KOSDAQ:A376270Market cap: ₩289.1b価格と性能株価の高値、安値、推移の概要GC過去の株価現在の株価₩10,320.0052週高値₩18,010.0052週安値₩8,630.00ベータ0.561ヶ月の変化11.93%3ヶ月変化-31.06%1年変化-31.38%3年間の変化-25.38%5年間の変化-67.70%IPOからの変化526.17%最新ニュースお知らせ • Apr 01Green Cross Holdings Corporation (KOSE:A005250) acquired 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) for KRW 50.5 billion.Green Cross Holdings Corporation (KOSE:A005250) acquired 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) for KRW 50.5 billion on March 31, 2026. A cash consideration of KRW 50.45 billion will be paid by Green Cross Holdings Corporation. As part of consideration, KRW 50.45 billion is paid towards common equity of GREEN CROSS WellBeing Corporation. The transaction will be financed through bank borrowing of KRW 50.45 billion. Green Cross Holdings Corporation (KOSE:A005250) completed the acquisition of 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) on March 31, 2026.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩13,730, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 8.9% over the past three years.お知らせ • Feb 12+ 1 more updateGreen Cross Holdings Corporation announces Annual dividendGreen Cross Holdings Corporation announced Annual dividend of KRW 300.0000 per share, ex-date on March 30, 2026 and record date on March 31, 2026.分析記事 • Nov 23Green Cross Holdings (KRX:005250) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfGreen Cross Holdings Corporation's ( KRX:005250 ) robust earnings report didn't manage to move the market for its...Valuation Update With 7 Day Price Move • Jun 10Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩17,090, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 8.1% over the past three years.分析記事 • Mar 25Green Cross Holdings' (KRX:005250) Strong Earnings Are Of Good QualityThe subdued stock price reaction suggests that Green Cross Holdings Corporation's ( KRX:005250 ) strong earnings didn't...最新情報をもっと見るRecent updatesお知らせ • Apr 01Green Cross Holdings Corporation (KOSE:A005250) acquired 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) for KRW 50.5 billion.Green Cross Holdings Corporation (KOSE:A005250) acquired 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) for KRW 50.5 billion on March 31, 2026. A cash consideration of KRW 50.45 billion will be paid by Green Cross Holdings Corporation. As part of consideration, KRW 50.45 billion is paid towards common equity of GREEN CROSS WellBeing Corporation. The transaction will be financed through bank borrowing of KRW 50.45 billion. Green Cross Holdings Corporation (KOSE:A005250) completed the acquisition of 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) on March 31, 2026.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩13,730, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 8.9% over the past three years.お知らせ • Feb 12+ 1 more updateGreen Cross Holdings Corporation announces Annual dividendGreen Cross Holdings Corporation announced Annual dividend of KRW 300.0000 per share, ex-date on March 30, 2026 and record date on March 31, 2026.分析記事 • Nov 23Green Cross Holdings (KRX:005250) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfGreen Cross Holdings Corporation's ( KRX:005250 ) robust earnings report didn't manage to move the market for its...Valuation Update With 7 Day Price Move • Jun 10Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩17,090, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 8.1% over the past three years.分析記事 • Mar 25Green Cross Holdings' (KRX:005250) Strong Earnings Are Of Good QualityThe subdued stock price reaction suggests that Green Cross Holdings Corporation's ( KRX:005250 ) strong earnings didn't...お知らせ • Feb 12Green Cross Holdings Corporation, Annual General Meeting, Mar 26, 2025Green Cross Holdings Corporation, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea分析記事 • Jan 17Green Cross Holdings Corporation's (KRX:005250) Price Is Right But Growth Is LackingYou may think that with a price-to-sales (or "P/S") ratio of 0.3x Green Cross Holdings Corporation ( KRX:005250 ) is...Upcoming Dividend • Dec 20Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 07 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).分析記事 • Dec 17Is Green Cross Holdings (KRX:005250) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...分析記事 • Aug 09Is Green Cross Holdings (KRX:005250) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...お知らせ • Jul 18China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) agreed to acquire 77.35% stake in Green Cross Hk Holdings Limited from Green Cross Holdings Corporation (KOSE:A005250) for approximately KRW 270 billion.China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) agreed to acquire 77.35% stake in Green Cross Hk Holdings Limited from Green Cross Holdings Corporation (KOSE:A005250) for approximately KRW 270 billion on July 17, 2024. A cash consideration of KRW 268.06 billion will be paid by China Resources Boya Bio-pharmaceutical Group for 97,558,858 shares. For the period ending December 31, 2023, Green Cross Hk Holdings Limited reported total revenue of KRW 45.88 billion and net loss of KRW 3.1 billion. As of December 31, 2023, Green Cross Hk Holdings Limited reported total debt of KRW 43.32 billion, total assets of KRW 144.86 billion and total common equity of KRW 101.55 billion.Upcoming Dividend • Dec 20Upcoming dividend of ₩300 per share at 1.9% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%).New Risk • Sep 11New major risk - Revenue and earnings growthEarnings have declined by 4.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Dividend is not well covered by earnings and cash flows. Payout ratio: 253% Paying a dividend despite having no free cash flows. Earnings have declined by 4.8% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin).Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩727 (vs ₩1,222 in FY 2021)Full year 2022 results: EPS: ₩727 (down from ₩1,222 in FY 2021). Revenue: ₩2.08t (up 13% from FY 2021). Net income: ₩32.8b (down 41% from FY 2021). Profit margin: 1.6% (down from 3.0% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Dec 21Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • May 22First quarter 2022 earnings released: ₩47.00 loss per share (vs ₩287 profit in 1Q 2021)First quarter 2022 results: ₩47.00 loss per share (down from ₩287 profit in 1Q 2021). Revenue: ₩502.4b (up 45% from 1Q 2021). Net loss: ₩1.95b (down 115% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 04 April 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Aug 27Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩33,100, the stock trades at a trailing P/E ratio of 23.2x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 12% over the past three years.分析記事 • Apr 28Know This Before Buying Green Cross Holdings Corporation (KRX:005250) For Its DividendIs Green Cross Holdings Corporation ( KRX:005250 ) a good dividend stock? How can we tell? Dividend paying companies...Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩38,000, the stock trades at a trailing P/E ratio of 28.4x. Average trailing P/E is 53x in the Biotechs industry in South Korea. Total loss to shareholders of 3.8% over the past three years.分析記事 • Mar 21Is Now The Time To Put Green Cross Holdings (KRX:005250) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Mar 01Green Cross Holdings (KRX:005250) Seems To Be Using A Lot Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • Feb 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩36,850, the stock is trading at a trailing P/E ratio of 29.8x, down from the previous P/E ratio of 35.4x. This compares to an average P/E of 55x in the Biotechs industry in South Korea. Total return to shareholders over the past three years is a loss of 9.5%.分析記事 • Feb 12If You Had Bought Green Cross Holdings (KRX:005250) Stock A Year Ago, You Could Pocket A 106% Gain TodayUnfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really...分析記事 • Jan 28Here's What Green Cross Holdings Corporation's (KRX:005250) Shareholder Ownership Structure Looks LikeIf you want to know who really controls Green Cross Holdings Corporation ( KRX:005250 ), then you'll have to look at...分析記事 • Jan 12We're Not So Sure You Should Rely on Green Cross Holdings's (KRX:005250) Statutory EarningsIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. However...Valuation Update With 7 Day Price Move • Jan 11Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩45,300, the stock is trading at a trailing P/E ratio of 36.7x, down from the previous P/E ratio of 43.4x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 18%.Is New 90 Day High Low • Jan 04New 90-day high: ₩53,600The company is up 131% from its price of ₩23,250 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period.Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩41,500, the stock is trading at a trailing P/E ratio of 33.6x, up from the previous P/E ratio of 28.2x. This compares to an average P/E of 56x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 10%.分析記事 • Dec 28Green Cross Holdings Corporation (KRX:005250) Investors Should Think About This Before Buying It For Its DividendDividend paying stocks like Green Cross Holdings Corporation ( KRX:005250 ) tend to be popular with investors, and for...Upcoming Dividend • Dec 22Upcoming Dividend of ₩325 Per ShareWill be paid on the 2nd of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.9% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.3%).分析記事 • Dec 13Green Cross Holdings Corporation's (KRX:005250) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?Green Cross Holdings (KRX:005250) has had a great run on the share market with its stock up by a significant 37% over...分析記事 • Nov 28Green Cross Holdings (KRX:005250) Use Of Debt Could Be Considered RiskySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Nov 28Optimistic Investors Push Green Cross Holdings Corporation (KRX:005250) Shares Up 63% But Growth Is LackingGreen Cross Holdings Corporation (KRX:005250) shareholders would be excited to see that the share price has had a...Is New 90 Day High Low • Nov 04New 90-day high: ₩35,000The company is up 17% from its price of ₩29,850 on 06 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period.Valuation Update With 7 Day Price Move • Nov 03Market bids up stock over the past weekAfter last week's 21% share price gain to ₩26,950, the stock is trading at a trailing P/E ratio of 40.1x, up from the previous P/E ratio of 33.1x. This compares to an average P/E of 65x in the Biotechs industry in South Korea. Total return to shareholders over the past three years is a loss of 26%.Is New 90 Day High Low • Oct 16New 90-day low: ₩22,000The company is down 9.0% from its price of ₩24,200 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: ₩22,350The company is down 7.0% from its price of ₩23,950 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.株主還元A005250KR BiotechsKR 市場7D-1.1%-4.7%-1.9%1Y-31.4%2.6%96.4%株主還元を見る業界別リターン: A005250過去 1 年間で2.6 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A005250は、過去 1 年間で96.4 % のリターンを上げたKR市場を下回りました。価格変動Is A005250's price volatile compared to industry and market?A005250 volatilityA005250 Average Weekly Movement8.6%Biotechs Industry Average Movement12.3%Market Average Movement9.8%10% most volatile stocks in KR Market17.6%10% least volatile stocks in KR Market5.1%安定した株価: A005250 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A005250の 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1967144Yong-Jun Huhwww.gccorp.comグリーンクロス・ホールディングスはバイオテクノロジー企業である。医療用医薬品と一般用医薬品、医薬品製造のための無菌充填・仕上げサービス、医薬品ロジスティクスサービスを提供。また、フォン・ウィルブランド病や原発性免疫不全症の血漿誘導体、mRNAインフルエンザ、炭疽、破傷風、ジフテリア、百日咳、結核、水痘のワクチン、後天性血栓性血小板減少性紫斑病、ファブリー、血友病、ハンターゼ、結腸癌、ハンター症候群の組換え治療薬、ガングリオシドーシスやアラジール症候群の低分子の研究開発も行っている。同社は、新薬や新技術の開発、臨床試験のために、バイオテクノロジー企業やアカデミアと提携や共同研究を行っている。ミドリ十字ホールディングスは1967年に設立され、韓国の龍仁市に本社を置いている。もっと見るGC Corp. 基礎のまとめGC の収益と売上を時価総額と比較するとどうか。A005250 基礎統計学時価総額₩453.28b収益（TTM）-₩88.86b売上高(TTM)₩2.49t0.2xP/Sレシオ-5.2xPER（株価収益率A005250 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A005250 損益計算書（TTM）収益₩2.49t売上原価₩1.79t売上総利益₩696.77bその他の費用₩785.63b収益-₩88.86b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.97kグロス・マージン27.96%純利益率-3.57%有利子負債／自己資本比率86.9%A005250 の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.9%現在の配当利回りn/a配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/20 11:54終値2026/08/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GC Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Sang-Hun LeeiM SecuritiesJae Hyun KwonMirae Asset Securities Co., Ltd.
お知らせ • Apr 01Green Cross Holdings Corporation (KOSE:A005250) acquired 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) for KRW 50.5 billion.Green Cross Holdings Corporation (KOSE:A005250) acquired 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) for KRW 50.5 billion on March 31, 2026. A cash consideration of KRW 50.45 billion will be paid by Green Cross Holdings Corporation. As part of consideration, KRW 50.45 billion is paid towards common equity of GREEN CROSS WellBeing Corporation. The transaction will be financed through bank borrowing of KRW 50.45 billion. Green Cross Holdings Corporation (KOSE:A005250) completed the acquisition of 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) on March 31, 2026.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩13,730, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 8.9% over the past three years.
お知らせ • Feb 12+ 1 more updateGreen Cross Holdings Corporation announces Annual dividendGreen Cross Holdings Corporation announced Annual dividend of KRW 300.0000 per share, ex-date on March 30, 2026 and record date on March 31, 2026.
分析記事 • Nov 23Green Cross Holdings (KRX:005250) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfGreen Cross Holdings Corporation's ( KRX:005250 ) robust earnings report didn't manage to move the market for its...
Valuation Update With 7 Day Price Move • Jun 10Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩17,090, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 8.1% over the past three years.
分析記事 • Mar 25Green Cross Holdings' (KRX:005250) Strong Earnings Are Of Good QualityThe subdued stock price reaction suggests that Green Cross Holdings Corporation's ( KRX:005250 ) strong earnings didn't...
お知らせ • Apr 01Green Cross Holdings Corporation (KOSE:A005250) acquired 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) for KRW 50.5 billion.Green Cross Holdings Corporation (KOSE:A005250) acquired 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) for KRW 50.5 billion on March 31, 2026. A cash consideration of KRW 50.45 billion will be paid by Green Cross Holdings Corporation. As part of consideration, KRW 50.45 billion is paid towards common equity of GREEN CROSS WellBeing Corporation. The transaction will be financed through bank borrowing of KRW 50.45 billion. Green Cross Holdings Corporation (KOSE:A005250) completed the acquisition of 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) on March 31, 2026.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩13,730, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 8.9% over the past three years.
お知らせ • Feb 12+ 1 more updateGreen Cross Holdings Corporation announces Annual dividendGreen Cross Holdings Corporation announced Annual dividend of KRW 300.0000 per share, ex-date on March 30, 2026 and record date on March 31, 2026.
分析記事 • Nov 23Green Cross Holdings (KRX:005250) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfGreen Cross Holdings Corporation's ( KRX:005250 ) robust earnings report didn't manage to move the market for its...
Valuation Update With 7 Day Price Move • Jun 10Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩17,090, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 8.1% over the past three years.
分析記事 • Mar 25Green Cross Holdings' (KRX:005250) Strong Earnings Are Of Good QualityThe subdued stock price reaction suggests that Green Cross Holdings Corporation's ( KRX:005250 ) strong earnings didn't...
お知らせ • Feb 12Green Cross Holdings Corporation, Annual General Meeting, Mar 26, 2025Green Cross Holdings Corporation, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea
分析記事 • Jan 17Green Cross Holdings Corporation's (KRX:005250) Price Is Right But Growth Is LackingYou may think that with a price-to-sales (or "P/S") ratio of 0.3x Green Cross Holdings Corporation ( KRX:005250 ) is...
Upcoming Dividend • Dec 20Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 07 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).
分析記事 • Dec 17Is Green Cross Holdings (KRX:005250) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
分析記事 • Aug 09Is Green Cross Holdings (KRX:005250) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
お知らせ • Jul 18China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) agreed to acquire 77.35% stake in Green Cross Hk Holdings Limited from Green Cross Holdings Corporation (KOSE:A005250) for approximately KRW 270 billion.China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) agreed to acquire 77.35% stake in Green Cross Hk Holdings Limited from Green Cross Holdings Corporation (KOSE:A005250) for approximately KRW 270 billion on July 17, 2024. A cash consideration of KRW 268.06 billion will be paid by China Resources Boya Bio-pharmaceutical Group for 97,558,858 shares. For the period ending December 31, 2023, Green Cross Hk Holdings Limited reported total revenue of KRW 45.88 billion and net loss of KRW 3.1 billion. As of December 31, 2023, Green Cross Hk Holdings Limited reported total debt of KRW 43.32 billion, total assets of KRW 144.86 billion and total common equity of KRW 101.55 billion.
Upcoming Dividend • Dec 20Upcoming dividend of ₩300 per share at 1.9% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%).
New Risk • Sep 11New major risk - Revenue and earnings growthEarnings have declined by 4.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Dividend is not well covered by earnings and cash flows. Payout ratio: 253% Paying a dividend despite having no free cash flows. Earnings have declined by 4.8% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin).
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩727 (vs ₩1,222 in FY 2021)Full year 2022 results: EPS: ₩727 (down from ₩1,222 in FY 2021). Revenue: ₩2.08t (up 13% from FY 2021). Net income: ₩32.8b (down 41% from FY 2021). Profit margin: 1.6% (down from 3.0% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Dec 21Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • May 22First quarter 2022 earnings released: ₩47.00 loss per share (vs ₩287 profit in 1Q 2021)First quarter 2022 results: ₩47.00 loss per share (down from ₩287 profit in 1Q 2021). Revenue: ₩502.4b (up 45% from 1Q 2021). Net loss: ₩1.95b (down 115% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 04 April 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Aug 27Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩33,100, the stock trades at a trailing P/E ratio of 23.2x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 12% over the past three years.
分析記事 • Apr 28Know This Before Buying Green Cross Holdings Corporation (KRX:005250) For Its DividendIs Green Cross Holdings Corporation ( KRX:005250 ) a good dividend stock? How can we tell? Dividend paying companies...
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩38,000, the stock trades at a trailing P/E ratio of 28.4x. Average trailing P/E is 53x in the Biotechs industry in South Korea. Total loss to shareholders of 3.8% over the past three years.
分析記事 • Mar 21Is Now The Time To Put Green Cross Holdings (KRX:005250) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
分析記事 • Mar 01Green Cross Holdings (KRX:005250) Seems To Be Using A Lot Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩36,850, the stock is trading at a trailing P/E ratio of 29.8x, down from the previous P/E ratio of 35.4x. This compares to an average P/E of 55x in the Biotechs industry in South Korea. Total return to shareholders over the past three years is a loss of 9.5%.
分析記事 • Feb 12If You Had Bought Green Cross Holdings (KRX:005250) Stock A Year Ago, You Could Pocket A 106% Gain TodayUnfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really...
分析記事 • Jan 28Here's What Green Cross Holdings Corporation's (KRX:005250) Shareholder Ownership Structure Looks LikeIf you want to know who really controls Green Cross Holdings Corporation ( KRX:005250 ), then you'll have to look at...
分析記事 • Jan 12We're Not So Sure You Should Rely on Green Cross Holdings's (KRX:005250) Statutory EarningsIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. However...
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩45,300, the stock is trading at a trailing P/E ratio of 36.7x, down from the previous P/E ratio of 43.4x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 18%.
Is New 90 Day High Low • Jan 04New 90-day high: ₩53,600The company is up 131% from its price of ₩23,250 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period.
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩41,500, the stock is trading at a trailing P/E ratio of 33.6x, up from the previous P/E ratio of 28.2x. This compares to an average P/E of 56x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 10%.
分析記事 • Dec 28Green Cross Holdings Corporation (KRX:005250) Investors Should Think About This Before Buying It For Its DividendDividend paying stocks like Green Cross Holdings Corporation ( KRX:005250 ) tend to be popular with investors, and for...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩325 Per ShareWill be paid on the 2nd of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.9% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.3%).
分析記事 • Dec 13Green Cross Holdings Corporation's (KRX:005250) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?Green Cross Holdings (KRX:005250) has had a great run on the share market with its stock up by a significant 37% over...
分析記事 • Nov 28Green Cross Holdings (KRX:005250) Use Of Debt Could Be Considered RiskySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Nov 28Optimistic Investors Push Green Cross Holdings Corporation (KRX:005250) Shares Up 63% But Growth Is LackingGreen Cross Holdings Corporation (KRX:005250) shareholders would be excited to see that the share price has had a...
Is New 90 Day High Low • Nov 04New 90-day high: ₩35,000The company is up 17% from its price of ₩29,850 on 06 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 03Market bids up stock over the past weekAfter last week's 21% share price gain to ₩26,950, the stock is trading at a trailing P/E ratio of 40.1x, up from the previous P/E ratio of 33.1x. This compares to an average P/E of 65x in the Biotechs industry in South Korea. Total return to shareholders over the past three years is a loss of 26%.
Is New 90 Day High Low • Oct 16New 90-day low: ₩22,000The company is down 9.0% from its price of ₩24,200 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: ₩22,350The company is down 7.0% from its price of ₩23,950 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.
